Physician profile
Cherese Y Collins
NPI 1194724062
$4,953.26
in general payments reported to CMS, 2019-2025
35 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $461 · 2021: $1,110 · 2022: $936 · 2023: $891 · 2024: $512 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.77 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,244.72 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $531.04 | 2021-2023 | |
| Evofem Biosciences, INC. | $305.57 | 2020-2025 | Phexxi, Solosec, Phexx |
| Myovant Sciences INC. | $273.57 | 2021-2022 | |
| Organon LLC | $229.85 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $198.14 | 2019-2024 | |
| Exeltis, USA INC. | $179.06 | 2020-2025 | Slynd |
| Sumitomo Pharma America, INC. | $174.33 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $172.97 | 2024-2025 | Veozah |
| Lupin INC. | $166.71 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $163.55 | 2019-2025 | Gardasil 9, Gardasil |
| Allergan, INC. | $162.15 | 2019-2020 | |
| Daiichi Sankyo INC. | $161.03 | 2019-2022 | |
| Amgen INC. | $158.43 | 2019-2024 | Evenity, Prolia |
| Avion Pharmaceuticals | $152.86 | 2019-2023 | Balcoltra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $132.73 | 2019-2024 | |
| Therapeuticsmd, INC. | $74.87 | 2019-2022 | |
| Ethicon US, LLC | $53.77 | 2021-2024 | Dermabond Prineo, Stratafix |
| Biohaven Pharmaceuticals, INC. | $44.28 | 2020-2021 | |
| Molnlycke Health Care US, LLC | $36.77 | 2020 | |
| Meditrina | $36.01 | 2021-2023 | |
| Duchesnay USA Incorporated | $32.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.50 | 2019 | |
| Minerva Surgical, INC | $26.22 | 2023 | |
| Hologic Sales and Service, LLC | $26.15 | 2022 | |
| Coopersurgical, INC. | $26.00 | 2022 | |
| Ascend Therapeutics US, LLC | $25.24 | 2021-2023 | |
| Mission Pharmacal Company | $19.54 | 2019 | |
| Agile Therapeutics, INC. | $17.98 | 2024 | Twirla |
| Novo Nordisk INC | $17.88 | 2021 | |
| Medtronic, INC. | $17.12 | 2023 | Truclear |
| Exact Sciences Corporation | $17.03 | 2023 | Cologuard Collection Kit |
| Optumhealth Care Solutions, LLC | $15.90 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Vertical Pharmaceuticals, LLC | $14.86 | 2019 | |
| Millicent US INC | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherese Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.